SURFACTANT THERAPY
Dr. (Prof.) Sanjata R. Chaudhary*, Dr. Kamran Faisal**
Prof. & Head Dept. of Pediatrics Patna Medical College.*, Junior Resident.**
Introduction:
Surfactant is a complex mixture of phospholipids (80%) proteins (10%) and neutral lipids (10%). Major Phospholipid is phosphatidyl choline and there are 4 surfactant specific proteins SP-A, SP-B, SP-C and SP-D; among which SP-B has get major surface tension lowering activity.

After the discovery that surfactant deficiency is responsible for pathophysiology of RDS surfactant therapy became popular.

Types of Surfactant:

Natural: Surfactant TA
Survanta (Beractant)
Infasurf (Calfactant)
Alveo fact
}
}
}
}
Bovine Lung

Curosurf-Porcine long (Poractant Alfa)

Synthetic: Exosurf
Lubricant/Sinaptitude/KL4

Pumactant 7 (AIEC)
Venticute (rsPC)



Indications:

  1. RDS is useful both in prevention and treatment
    Prophylactic - Birth weight <1200 gm Larger neonates with evidence of pulmonary immaturity
    1. Criteria: Premature infants on CPAP with arterial / alveolar 02
      Tension ratio i.e., a/APO2-0.22-0.35 (mean 0.26)
      Neonate with moderate to severe RDS
    2. Criteria: Infants requiring mechanical ventilation
      1. Fractional Concentration of inspired 02 i.e., FiO2> 40%
      2. Mean airway pressure> 0.6 Kpa (7 cm H2O)
  2. Interm infants and older children, respiratory failure due to
    • MAS
    • Pneumonias
    • PPHN
    • BPD
    • Acute Lung injury
  3. As vehicle to carry other therapeutic agents e.g., rh SOd (recombinant human super oxide dismutase)

Benefits:
Improves Oxygenation; Reduces air leaks (Pneumothorax / Pulm interstitial Emphysema by 50%).
  • Reduces duration of ventilatory support
  • Lowers mortality rate by 30%
  • Neither beneficial nor delirious effect on growth and neuro developmental parameter
  • Inconclusive data to support reduction in IVH / NEC / R.O.P. or CLD

Dosage and Administration:
  • Survanta - 4 ml/kg/dose at least 6 hrs apart (maximim 4 doses)
  • Infasurf - 3 ml/kg/dose (12 hrs apart)
  • Exosurf - 5 ml/kg/dose at least 12 hrs apart
  • Curosurf - 2.5 ml/kg/dose (initial) 1.25 ml/kg letter at least 12 hrs apart

Method of Administration:
As bolus intratracheally through ET tube by instillation into a 5 French end hole catheter inserted through ET tube with the tip of catheter inserted just beyond the end of ET tube and above the infant's carina. It can also be given via a side port adapter.

Considerations:

  • Not to shake vials: open vials can be kept at 2-8 degree C is open vials should not be frozen.
  • Suction ET tube before administration and delay suctioning post administration as long as possible
    (minimum 1 hour).
  • Slow administration by infusion pump / Nebulization has not shown improved result.


Monitoring:

  • Access: ET tube potency and correct anatomic location before administration of surfactant.
  • Monitor SO2 & HR continuously during administration of doses
  • After each dose monitor ABG and correct it if abnormal

Adverse Reaction: Transient Bradycardia, Hypoxemia, Pallor, Vasoconstriction, Hypotension, ET tube blockage, Hypercapnea, Apnea, HTN may occur.

Key Messages:
Surfactant reduces death in premature neonates with respiratory distress syndrome.
Surfactant should be administrated early in neonates requiring mechanical ventilation for RDS.
Surfactant therapy is cost effective in developing countries and antenatal steroids / CPAP / supportive care is important to improve outcomes.
How to Cite URL :
Chaudhary R S ( D, Faisal K D.. Available From : http://www.pediatriconcall.com/fordoctor/ Conference_abstracts/report.aspx?reportid=470
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.